Dear Editor,

Middle East respiratory syndrome coronavirus (MERS-CoV), first isolated in 2012, has emerged zoonotically among humans (van Boheemen *et al.* [@CR5]). Since then, MERS-CoV continues to be a public health concern, with a fatality rate of 35%. On-going MERS-CoV outbreaks highlight the urgent need for the development of interventional measures, including an effective vaccine against MERS-CoV infection. Currently, no licensed therapeutic or vaccine is available (Okba *et al.* [@CR4]).

MERS-CoV spike (S) protein mediates coronaviral penetration into host cells via initial interaction with the host cell surface receptor. Based on the major immunodominant region of S protein, vaccines against MERS-CoV infection have been developed using purified coronaviral S protein and DNA or viral vector-based vaccines expressing full-length MERS-CoV S protein or part of the S protein (Okba *et al.* [@CR4]). However, efforts are required to achieve optimal protective responses, such as a higher titer of neutralizing antibody and protection against MERS-CoV infection.

Virus-like particles (VLPs) are similar in size and morphology to intact virions, thereby rendering them ideal candidates as antigens or immunogens. Since VLPs cannot replicate in humans or revert to a pathogenic form, they are suitable candidates for vaccine development, especially those against life-threatening viruses such as SARS-CoV or MERS-CoV, which cause high morbidity and death. By co-expressing the *S*, envelope (*E*), and membrane (*M*) genes, Wang *et al.* generated VLPs of MERS-S ([@CR6]). However, it is difficult to generate these VLPs in large amounts owing to the lack of an efficient viral core protein. Chimeric VLPs (cVLPs) of SARS-CoV, containing the SARS S protein and the matrix protein of influenza virus using the baculovirus insect cell expression system, completely protected mice from death when administered intramuscularly or intranasally in the absence of an adjuvant (Liu *et al.* [@CR3]). The use of influenza M1 as a core protein to generate cVLPs for other viruses is reportedly a promising approach, potentially increasing the yield and activating antigen-specific B cells for differentiation and antibody secretion (Liu *et al.* [@CR3]). In the present study, we developed a novel type of cVLPs containing modified MERS-CoV S protein and the avian influenza matrix 1 (M1) protein, using a baculovirus insect cell expression system.

We first constructed a recombinant plasmid pFastBacDual-M1-St/HAk, using a similar strategy to that described previously (Liu *et al.* [@CR3]), wherein a modified spike (St/HAk) of MERS-CoV (aa 1 to 1295 of MERS-CoV Spike, codon optimized DNA sequence based on Genbank:DQ420166.1, fused to aa 531-568 of H5N1 HA) and matrix protein 1 (M1) of A/Anhui/01/2005 (H5N1) (aa 1 to 758 of H5N1 M1 codon optimized DNA sequence based on GenBank: HM172159.1) were expressed, as shown in Fig. [1](#Fig1){ref-type="fig"}A. To construct the St/HAk, the transmembrane and carboxyl termini (TM/CT, aa 1296 to 1353 of MERS-CoV Spike) of MERS S protein were replaced with the corresponding segment (TM/CT) of HA-derived A/Anhui/01/2005 (H5N1). Thus, the recombinant *St/HAk* gene contained the ectodomain of MERS-CoV Spike and TM/CT of H5N1 HA. pFastBacDual-M1-St/HAk was digested with restriction enzymes *Kpn*I and *Nhe*I. Further sequenced to ensure the accuracy of the sequences of M1 and St/HAk. The tandem chimeric S/M1 plasmid pFastBacDual-M1-St/HAk was transformed into competent cells of DH10Bac™ (Invitrogen, California, USA) to generate recombinant bacmids (Bacmid M1-St/HAk), and verified via PCR. Purified recombinant bacmid DNA was transfected into Sf9 cells (ATCC CRL-1711) to generate recombinant baculoviral M1-St/HAk, using a Bac-to-Bac baculoviral expression system (Invitrogen). Harvested Sf9 cells infected with baculovirus M1-St/HAk were lysed with SDS-PAGE buffer. Recombinant proteins were identified via Western blot analysis and indirect immunofluorescence (Lan *et al.* [@CR2]; Deng *et al.* [@CR1]).Fig. 1Robust humoral immunity in mice induced by the novel chimeric virus-like particles (cVLPs) vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. **A** A schematic representation of the recombinant baculoviral expression system expressing Middle East respiratory syndrome coronaviral S and avian influenza matrix 1 based on the recombinant plasmid pFastBacDual. **B** Expression of the recombinant protein in infected cells at an optimal MOI (MOI = 5) analyzed by Western blot. Proteins were harvested at different time points (24, 72 and 96 h). S protein expression was analyzed by immunoblotting using a monoclonal anti-S (MERS-CoV) and anti-M1 (H5N1) antibodies. The top panel indicate S expression; bottom panel, M1 expression. **C** The morphology of cVLPs assessed via transmission electron microscopy and immuno-electron microscopy. Figure 1**C**-a shows the results of negative staining assessed via electron microscopy. Figure 1**C**-b shows the results of immuno-electron microscopy. cVLPs were incubated with murine monoclonal antibodies against MERS-CoV S protein and probed using a gold-labeled goat anti-mouse IgG antibody. Bar = 100 nm. **D** S-specific IgG antibodies detected by ELISA in the serum of immunized mice. The titers of S-specific total IgG in the serum of mice 2 weeks after the second (6 weeks) and the third immunization (10 weeks). **E** Neutralizing antibody titer in the serum of mice, detected by a pseudovirus neutralization assay of MERS-CoV 2 weeks after the third immunization (10 weeks), indicated as pI50. A + C implies the control group of mice injected with adjuvants aluminum (A) plus CpG (C).

Thereafter, we harvested the P3 stock of recombinant baculovirus M1-St/HAk from infected Sf9 cells at a titer of 8 × 10^7^ PFU/mL. Suspended High Five™ cells were infected by recombinant baculovirus M1-St/HAk at a multiplicity of infection (MOI) of 1, 5, and 10, and harvested at different time points (24, 72, and 96 h). Protein expression was analyzed via SDS-PAGE and Western blot analysis to determine the optimal conditions. Recombinant M1-St/HAk protein expression was highest at a MOI of 5 after 72 h. After large-scale amplification, the recombinant proteins yielded bands at approximately \~ 157 kDa, which represents a monomer of the S protein ectodomain, a \~ 110-kDa band, which represents the cleavage of S glycoprotein into an amino-terminal domain (S1), and a 25-kDa band, which represents the M1 protein of H5N1 (Fig. [1](#Fig1){ref-type="fig"}B), thereby confirming MERS-CoV S protein and H5N1 M1 protein expression. After purification via ultracentrifugation at 4 ºC, 3,000 rpm for 2 h, the cVLPs of MERS-S were negatively stained and observed via transmission electron microscope. Enveloped VLPs displayed a spheroid morphology, with a diameter of 80--100 nm and displayed morphological similarity with CoV virions, with enveloped spikes arranged in a crown shape (Fig. [1](#Fig1){ref-type="fig"}C-a). After labelling with murine monoclonal antibodies against S protein of MERS-CoV and gold-labeled goat anti-mouse IgG antibody, S specific proteins shown as black pellets were observed on the cVLP~S~ (Fig. [1](#Fig1){ref-type="fig"}C-b). These results indicate that chimeric MERS VLPs are morphologically similar to native MERS-CoV (<https://www.cdc.gov/coronavirus/mers/photos.html>).

To assess the immunogenicity of cVLP~S~ in mice, 6--8-week-old female BALB/c mice were intramuscularly injected with 1 μg of cVLPs of MERS-S adjuvanted with 100 μL of aluminum (A) and 10 μg of CpG (C). Simultaneously, the mice of control group inoculated with adjutants (A + C) only. All mice were immunized thrice at 4-week intervals. Mice were bled via the venae angularis and serum was harvested from whole blood to determine IgG levels via enzyme-linked immunosorbent assay (ELISA) and neutralization activity was assessed via the pseudovirus neutralization assay for MERS-CoV (Lan *et al.* [@CR2]; Deng *et al.* [@CR1]) As shown in Fig. [1](#Fig1){ref-type="fig"}D, 2 weeks after the second immunization, the total S protein-specific IgG titer approached 1:80,000 in the VLP group, being significantly higher than that in the control group. After the third immunization, the IgG titer was further elevated (more than 10^5^). More importantly, high titers of neutralization antibodies (at a serum dilution of 1:320, \> 50% neutralizing activity based on the pseudovirus neutralization assay, indicated as pI~50~ = 320) were also detected in mice immunized with cVLPs (Fig. [1](#Fig1){ref-type="fig"}E).

We developed immunogenic cVLPs of MERS-S via co-expression of H5N1 M1 protein and MERS-CoV S protein in a baculoviral expression system. The present results indicate that cVLPs with surface expression of MERS-CoV S protein, morphologically emulating the native virus, are promising candidates for prophylactic vaccines for MERS-CoV infections. A similar strategy was adopted to formulate cVLPs of SARS-CoV (Liu *et al.* [@CR3]). The present results thus indicate that cVLPs of MERS-S mimic wild type viral morphology and induce robust S-specific humoral immune responses in mice. In the future study, we intend to use a similar platform to develop cVLPs of other CoVs or highly pathogenic viruses to further validate the present strategy and to purify cVLPs of MERS-S on a large scale to evaluate the protective effect of cVLPs in animal models of infection.
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